BALDNESS CURE BY 2020 – RCH-01 ALOPECIA TREATMENT

Related Articles

SCALP MICROPIGMENTATION – THE NON-SURGICAL FASTEST REMEDY FOR BALDNESS

March 11, 2021

FACIAL AND SCALP EXERCISES GUARANTEED TO STOP HAIR LOSS

February 28, 2021

6 BEST EXERCISES FOR HAIR GROWTH AND PREVENT BALDNESS

February 17, 2021

Today’s article is a good news for all hair loss patients including both men and women. Yes this is on the most recent treatment for hair loss by Replicel – that’s RCH-01.

This RCH-01 hair loss treatment trial has completed its phase 1 clinical trials with some strong positive data. In this video, will know the latest happenings on this Replicel company’s RCH-01 hair restoration product, the so called permanent baldness cure.

We will also learn how this products works – that is the mechanism of action and how this is used on a patient with alopecia.

The latest news! As on On March 05 2019, RepliCel Life Sciences Inc. announced its successful completetion of phase 1 human clinical trials of  its product RCH-01 – Hair Cell restoration product for the treatment of male pattern baldness or androgenetic alopecia.

The company RepliCel was first set up in Japan in 2013 and now in partnership with Shiseido, together have brought a  lot of changes since then.  Shiseido, has currently funded a human clinical study of RCH-01 at Tokyo Medical University Hospital and Toho University Ohasi Medical Center in Japan.

With the clinical study of RCH-01 now successfully completed in Japan, RepliCel expects Shiseido to declare its near-term plans for RCH-01.

RCH 01 has Alternative Names: DSC cell therapy – RepliCel; Hair cell replacement therapy – RepliCel; Human autologous hair follicle cells RepliCel Hair-01

This RCH-01 is based on the principle of advanced cellular regeneration involving the dermal sheath cup cells, hence its also called DSC cell therapy.

Replicel’s RCH-01 hair growth treatment is done by first extracting and then culturing a person’s own hair follicle cells and then re-injecting the modified DHT resistant hair follicle cells back into their scalp.

What they do is Firstly, through a simple punch biopsy, they isolate the cells from healthy hair follicles from the patient’s scalp. Then the hair follicles are dissected and the dermal papilla portion is cut off. This dermal papilla is the region where the DHT receptors are located and are responsible for damage by the DHT – that’s dihydroxytestosterone.  If you have n’t watched my DHT and hair loss episode, please check that from an endscreen link to understand this mechanism.
Well, These cells are removed from the remaining follicle and cultured in a growth medium. The cells are replicated or multiplied into millions of new cells and then these are drawn into a syringe. This syringe is inserted into the patients scalp skin and injected back into the patient.  Remember, these are patient’s own replicated cells and hence no adverse reaction or side effects and this is very much similar to PRP treatment for hair loss, where patients own platelet rich plasma is injected. You can also check out my detailed video on this PRP mesotherapy for hairloss.
Well, These cells after injection into the scalp, scatter and migrate to attach to the dormant hair follicles and rejuvenate and stimulate them to grow further and also they have the ability to induce the formation of new healthy hair follicles and multiply over a period of time to give rise to new hair which emerges out of the skin surface.

More details should be disclosed by the company once they launch the product.

The Current Status of the product: Shiseido’s Japan phase 1 clinical trial started in 3rd quarter 2016 is now complete as per company’s website and news. Now whether they enter into phase 2 or directly launch the product. Its still not clear. But likely possibility is the treatment could become available in 2020. Because of the strong positive data from this trial, there is a strong possibility that Shiseido might decide to launch the product in Japan first. So keep your fingers crossed for the launch.

REFERENCES:

https://adisinsight.springer.com/drugs/800034931

https://www.prnewswire.com/news-releases/replicel-ceo-provides-2019-shareholder-update-300806460.html

https://replicel.com/patients/hair-study

Study Results phase 1 – https://goo.gl/WF66UA